Sylvia Wagner studied Chemistry at the University Karlsruhe. She did her PhD thesis at the Fraunhofer IBMT, where she is Group Manager of the Preclinical Nanotechnology & Nanotoxicology group since 2008 and Head of Department Bioprocessing & Bioanalytics since 2015. Her main research topics are focused on nanobiotechnology and development of in vitro/ex vivo models for preclinical testing of new nanoparticulate formulations and nanosafety issues. For example, formulations for the specific drug targeting (e.g., tumor targeting) as well as for crossing of biological barriers (e.g., blood-brain barrier or gastrointestinal barrier) are mainly on focus. Sylvia Wagner studied Chemistry at the University Karlsruhe. She did her PhD thesis at the Fraunhofer IBMT, where she is Group Manager of the Preclinical Nanotechnology & Nanotoxicology group since 2008 and Head of Department Bioprocessing & Bioanalytics since 2015. Her main research topics are focused on nanobiotechnology and development of in vitro/ex vivo models for preclinical testing of new nanoparticulate formulations and nanosafety issues. For example, formulations for the specific drug targeting (e.g., tumor targeting) as well as for crossing of biological barriers (e.g., blood-brain barrier or gastrointestinal barrier) are mainly on focus.

Medicinal chemistry